The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Colomba Falcone, Diego Geroldi, Maria P. Buzzi, Enzo Emanuele, Yusuf Yilmaz, Jacopo M. Fontana, Luigi Vignali, Chiara Boiocchi, Ilaria Sbarsi, Mariaclara Cuccia

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalArchives of Medical Research
Volume39
Issue number3
DOIs
Publication statusPublished - Apr 2008

Keywords

  • Genetics
  • Polymorphism
  • Prognosis
  • Receptor for advanced glycation end products

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease'. Together they form a unique fingerprint.

Cite this